This grant will fund research using data from expanded access to investigational drugs for ALS patients who are ineligible for clinical trials, aiming to improve prevention, diagnosis, or treatment of ALS.
NIH plans to support research using data from expanded access protocols that provide investigational treatments to people with ALS; applications are not yet being solicited.
Funds research to develop medical products for treating or curing ALS and other rare neurodegenerative diseases in adults and children.
The Hoffman ALS Clinical Trial Awards Program supports researchers conducting early-stage trials of ALS treatments and imaging tracers to generate safety, dosing, and biomarker data for later development.
This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.
This grant supports combined Phase 1/2a clinical trials testing new drugs (excluding amyloid/tau targets) for Alzheimer's, using a milestone-driven approach.